|
IMVT | Immunovant, Inc. |
|
|
IMVT | Immunovant, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.25 |
| Leverage | 6.30% |
| Market Cap | $ 3.9B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -462.9m |
| Margin | -19212.04% |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.